Recent Updates
Recently added Catalysts
INCY Positive Sentiment

Opzelura® (Ruxolitinib)-Creme ist der erste steroidfreie topische JAK-Hemmer, der in der Europäischen Union für Erwachsene mit mittelschwerer atopischer Dermatitis zugelassen wurde

Wednesday, July 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Incyte announced that the European Commission has approved Opzelura® (Ruxolitinib) cream for treating moderate atopic dermatitis in adults. This approval is significant as it offers a new, steroid-free treatment option for patients who have not responded adequately to topical corticosteroids and calcineurin inhibitors. The approval is seen as a major milestone for both Incyte and patients in Europe.
Price reaction · baseline $125.93 (2026-07-29T16:18:00.000Z) · hit during market hours · 2 other INCY headline(s) in the window, move may be shared
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • First steroid-free topical JAK inhibitor approved in the EU.
  • Provides a new treatment option for adults with moderate atopic dermatitis.
  • Approval marks a significant milestone for Incyte and patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
2.4%
average across 15 past catalysts
Lead asset
Retifanlimab
Phase 1 · Unmethylated Glioblastoma

Full Press Release Details

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die Europäische Kommission (EK) die Opzelura® (Ruxolitinib)-Creme zur Behandlung mittelschwerer atopischer Dermatitis (AD) bei erwachsenen Patienten zugelassen hat, bei denen topische Kortikosteroide (TCS) und topische Calcineurin-Hemmer (TCI) unzureichend oder ungeeignet sind. „Die Zulassung von Opzelura durch die Europäische Kommission ist ein wichtiger Meilenstein für Erwachsene in Europa, die an mittelschwer

Frequently Asked Questions

What is Opzelura®?

Opzelura® is a steroid-free topical JAK inhibitor cream used to treat moderate atopic dermatitis.

Who is Opzelura® approved for?

It is approved for adults with moderate atopic dermatitis who have not responded well to other treatments.

What does the EU approval signify?

The approval signifies a significant milestone in providing new treatment options for patients in Europe.

What are the alternatives to Opzelura®?

Alternatives include topical corticosteroids and topical calcineurin inhibitors, which may be inadequate or unsuitable.

ShareAdd on Google
Tags: INCY Incyte Opzelura Ruxolitinib atopic dermatitis EU approval
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$4536M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RetifanlimabPhase 1
Unmethylated Glioblastoma →

Catalyst track record

+34%
best trade around INCY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for INCY.

See every catalyst's timing & PoA →